Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Subscribe To Our Newsletter & Stay Updated